Acipimox potentiates growth hormone (GH) response to GH-releasing hormone with or without pyridostigmine by lowering serum free fatty acid in normal and obese subjects.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Journal of Clinical Endocrinology and Metabolism

• Publication date

  1995-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1210/JCEM.80.8.7629249PMID 7629249
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reduced growth hormone response to L-dopa and pyridostigmine in obesity.

  1994cited by this paper
• Influence of pyridostigmine on growth hormone (GH) response to GH-releasing hormone pre- and postprandially in normal and obese subjects.

  1992cited by this paper
• Sleep-related growth hormone secretion in human obesity: effect of dietary treatment.

  1991cited by this paper
• Growth hormone (GH) autofeedback on GH response to GH-releasing hormone. Role of free fatty acids and somatostatin.

  1991cited by this paper
• Effect of acipimox, a lipid lowering drug, on growth hormone (GH) response to GH-releasing hormone in normal subjects

  1990cited by this paper
• Pyridostigmine enhances, but does not normalise, the GH response to GH-releasing hormone in obese subjects.

  1990cited by this paper
• Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone secretion elicited by clonidine, arginine, or hypoglycemia in normal and obese subjects.

  1990cited by this paper
• Endocrine aspects of obesity.

  1989cited by this paper
• Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.

  1989cited by this paper
• Free fatty acids block growth hormone (GH) releasing hormone-stimulated GH secretion in man directly at the pituitary.

  1987cited by this paper
• Enhancement of cholinergic tone by pyridostigmine promotes both basal and growth hormone (GH)-releasing hormone-induced GH secretion in children of short stature.

  1987cited by this paper
• GH FEEDBACK OCCURS THROUGH MODULATION OF HYPOTHALAMIC SOMATOSTATIN UNDER CHOLINERGIC CONTROL: STUDIES WITH PYRIDOSTIGMINE AND GHRH

  1987cited by this paper
• Potentiation of cholinergic tone by pyridostigmine bromide re-instates and potentiates the growth hormone responsiveness to intermittent administration of growth hormone-releasing factor in man.

  1986cited by this paper
• Cholinergic agonist and antagonist drugs modulate the growth hormone response to growth hormone-releasing hormone in the rat: evidence for mediation by somatostatin.

  1986cited by this paper
• Impaired growth hormone responses to growth hormone-releasing factor in obesity. A pituitary defect reversed with weight reduction.

  1984cited by this paper
• Effect of agonists and antagonists of cholinergic neurotransmission on growth hormone release in the dog.

  1983cited by this paper
• Inhibition of lipolysis by nicotinic acid and by acipimox

  1980cited by this paper
• Growth hormone response to propranolol and L--dopa in obese subjects.

  1978cited by this paper
• Studies on the relationship between plasma free fatty acids and growth hormone secretion in man.

  1972cited by this paper

• Deficits in voice and multisensory processing in patients with Prader-Willi syndrome.

  2016cites this paper
• The robustness of diagnostic tests for GH deficiency in adults.

  2015cites this paper
• Nonalcoholic fatty liver disease is associated with increased GHBP and reduced GH/IGF‐I levels

  2012cites this paper
• Influence of Body Mass Index on Growth Hormone Responses to Classic Provocative Tests in Children with Short Stature

  2011cites this paper
• REGULATION OF IMMEDIATE EARLY AND EPITHELIAL-MESENCHYMAL TRANSITION GENES EXPRESSION BY ADIPOCYTOKINES IN THE FEMALE REPRODUCTIVE TRACT

  2011cites this paper
• The diagnosis of GH deficiency in obese patients: a reappraisal with GHRH plus arginine testing after pharmacological blockade of lipolysis.

  2010cites this paper
• GH/IGF-I Regulation in Obesity – Mechanisms and Practical Consequences in Children and Adults

  2010cites this paper
• Growth hormone secretory in healthy aged women and men of Tunisian population

  2009cites this paper
• Combination therapy with acipimox enhances the effect of growth hormone treatment on linear body growth in the normal and small-for-gestational-age rat.

  2006cites this paper
• Pubertal alterations in growth and body composition: IX. Altered spontaneous secretion and metabolic clearance of growth hormone in overweight youth.

  2005cites this paper
• Influence of body mass index and gender on growth hormone (GH) responses to GH-releasing hormone plus arginine and insulin tolerance tests.

  2005cites this paper
• Role of Mitochondrial Uncoupling Protein 2 (UCP2) in Modulation of Adiposity

  2004cites this paper
• Acipimox enhances spontaneous growth hormone secretion in obese women.

  2004cites this paper
• Diagnosis of growth hormone deficiency after pituitary surgery: the combined acipimox/GH‐releasing hormone test

  2003influential citation
• Nutritional status in the neuroendocrine control of growth hormone secretion: the model of anorexia nervosa.

  2003cites this paper
• Evaluation of growth hormone stimulation tests in cured acromegalic patients.

  2003cites this paper
• Impact of the GH-cortisol ratio on the age-dependent changes in body composition.

  2002cites this paper
• Obesity and Hormonal Abnormalities

  2002cites this paper
• Effect of IGF-I administration on growth hormone secretion in obese subjects

  2001cites this paper
• Growth Hormone and Adipocyte Function in Obesity

  2000cites this paper
• Reduction of free fatty acids by acipimox enhances the growth hormone (GH) responses to GH-releasing peptide 2 in elderly men.

  2000cites this paper
• The effect of circulating non‐esterified fatty acids on the entero‐insular axis

  1999cites this paper
• GH-binding protein in obese men with varying glucose tolerance: relationship to body fat distribution, insulin secretion and the GH-IGF-I axis.

  1999cites this paper
• Low-Dose Growth Hormone Treatment with Diet Restriction Accelerates Body Fat Loss, Exerts Anabolic Effect and Improves Growth Hormone Secretory Dysfunction in Obese Adults

  1999influential citation
• Growth hormone in obesity

  1999cites this paper
• Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human.

  1998cites this paper
• The effect of body composition on hexarelin‐induced growth hormone release in normal elderly subjects

  1998cites this paper
• Variability in growth hormone stimulation tests.

  1998cites this paper
• The diagnosis of growth hormone deficiency in children and adults.

  1998cites this paper
• Abnormal pulsatile secretion of growth hormone in non‐insulin‐dependent diabetes mellitus

  1997cites this paper
• Effect of aging on the sensitivity of growth hormone secretion to insulin-like growth factor-I negative feedback.

  1997cites this paper
• Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone

  1997cites this paper
• Maximal secretory capacity of somatotrope cells in obesity: comparison with GH deficiency

  1997cites this paper
• Acute pharmacological reduction of plasma free fatty acids enhances the growth hormone (GH)-releasing hormone-mediated GH secretion in patients with Cushing's syndrome.

  1997cites this paper
• Somatotrope responsiveness to Hexarelin, a synthetic hexapeptide, is refractory to the inhibitory effect of glucose in obesity.

  1996cites this paper
• Long-term administration of acipimox potentiates growth hormone response to growth hormone-releasing hormone by decreasing serum free fatty acid in obesity.

  1996cites this paper
• The endocrinology of obesity.

  1996cites this paper